In an interview with CURE, Dr. Lakshmi Nayak explains how an FDA label update expands Yescarta access for relapsed or refractory primary CNS lymphoma.
Dr. Lakshmi Nayak
Advertisement
A neuro-oncologist at Dana-Farber Cancer Institute and director of the Center for CNS Lymphoma.
Articles by Dr. Lakshmi Nayak
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Trodelvy Alone or With Keytruda for First-Line Triple-Negative Breast Cancer
2
FDA Approves Ibrance Combo for Maintenance Treatment of HR-Positive, HER2-Positive Metastatic Breast Cancer
3
The Life I Did Not Expect After Cancer
4
Living With Cancer: What the Mariana Trench and Cancer Have in Common
5